قالب وردپرس درنا توس
Home / Health / CEO of the company & # 39; Female Viagra & # 39 ;: New competing drug will "continue to drive growth"

CEO of the company & # 39; Female Viagra & # 39 ;: New competing drug will "continue to drive growth"



RALEIGH – Cindy Eckert, CEO of Sprout Pharmaceuticals of Raleigh, welcomes news that her company's so-called "female Viagra" is now competing on the market for the treatment of women's sexual disorders.

Addyi drug, also known as the "little pink pill," sells well. Eckert says Vyleesi's FDA approval of Vyleesi on Friday will pay more attention to the discussion and treatment of pre-menopausal women suffering from hypoactive (low) sexual desire Disorder (HSDD).

"The scion triples from year to year, and today's news will only drive this forward," said Eckert on Saturday morning to WRAL TechWire.

FDA approves rival for "female Viagra" from Sprout Pharmaceuticals of Raleigh

There are differences between the drugs. For example, Addyi is a pill; Vylessi is an injection.

Eckert fought the FDA in 2015 to obtain approval for the first female medicine, and in part argued that men had access to treatment for sexual disorders at the time, but women did not.

Addyi

"When we broke through with Addyi, the first treatment for low libido in women, our goal was not to be the last," Eckert said. "We wanted to smash a blanket, create a category, and make an overdue conversation about the right of women to desire."

She pointed out that women now have a choice that matters to them.

"Women who have options Has the mission come true and patients win as we increasingly discuss this common disease? "Eckert said.

"Considering what happened to the ED treatment [erectile dysfunction] when more than just Viagra was available, growth was explosive due to the shift. Eckert and his investors have Sprout in 2015 for $ 1 billion to Valeant Pharmaceuticals sold, and two years later, they and a group of lenders have repurchased the company.

Since the repurchase of Addyi, Sprout has taken a drastic step in reducing its monthly costs to $ 25 through insurance coverage or $ 99 by registered delivery. The price of Addyi was several hundred dollars before Sprout regained control.

Valeant returned rights to Addyi with virtually no cost and granted Sprout a $ 25 million loan to relaunch the company as a separate company.


Source link